文献速递腹部介入PETMRCT

F-18 FDG灌注PET:术中评估肝脏肿瘤消融边缘

F-18 FDG perfusion PET: intraprocedural assessment of the liver tumor ablation margin.
PubMed 文献 · Abdom Radiol (NY) · 2021-02-19

本研究纳入20例成人患者共31个FDG高摄取肝肿瘤,在FDG PET/CT引导微波消融术中行FDG灌注PET评估消融边缘,并与术后增强MRI及随访结果对照。灌注PET使两名阅片者均更常判定消融边缘可完全评估(OR 69.7),消融边缘≥5 mm与低的不完全消融/局部进展风险相关(HR 0.08和0.02)。

要点

  • 术中FDG灌注PET较术后MRI更常可完全评估消融边缘(OR 69.7)。
  • 灌注PET测得最小消融边缘≥5 mm与低局部进展风险相关(HR 0.08和0.02)。
  • 术中灌注PET促使对2个肿瘤追加重叠消融,两者均未进展。

关键影像表现/征象

  • 术中FDG灌注PET促使对2个肿瘤追加重叠消融,两者均未进展。
  • 不完全消融或局部进展发生于8/31(26%)个肿瘤,重复消融后二次有效率为26/31(84%)。
  • 两名阅片者用灌注PET判定消融边缘完全可评估的频率均高于MRI(OR 69.7;CI 6.0,806.6;p = 0.001)。

诊断标准与关键数值

  • 灌注PET最小消融边缘≥5 mm与两名阅片者判定的低不完全消融/局部进展风险相关(HR 0.08和0.02,p < 0.001)。

临床应用与阅片要点

  • 术中FDG灌注PET可用于评估肝肿瘤微波消融边缘,最小边缘≥5 mm与低局部进展风险相关。
  • 灌注PET判定消融边缘可评估性优于术后增强MRI(OR 69.7;CI 6.0,806.6;p = 0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate 18F-fluorodeoxyglucose (FDG) perfusion PET during FDG PET/CT-guided liver tumor microwave ablation procedures for assessing the ablation margin and correlating minimum margin measurements with local progression.

METHODS: This IRB-approved, HIPAA-compliant study included 20 adult patients (11 M, 9 F; mean age 65) undergoing FDG PET/CT-guided liver microwave ablation to treat 31 FDG-avid tumors. Intraprocedural FDG perfusion PET was performed to assess the ablation margin. Intraprocedural decisions regarding overlapping ablations were recorded. Two readers retrospectively interpreted intraprocedural perfusion PET and postprocedural contrast-enhanced MRI. Assessability of the ablation margin and minimum margin measurements were recorded. Imaging follow-up for local progression ranged from 30 to 574 days (mean 310). Regression modeling of minimum margin measurements was performed. Hazard ratios were calculated to correlate an ablation margin threshold of 5 mm with outcomes.

RESULTS: Intraprocedural perfusion PET prompted additional overlapping ablations of two tumors, neither of which progressed. Incomplete ablation or local progression occurred in 8/31 (26%) tumors. With repeat ablation, secondary efficacy was 26 (84%) of 31. Both study readers deemed ablation margins fully assessable more often using perfusion PET than MRI (OR 69.7; CI 6.0, 806.6; p = 0.001). Minimum ablation margins ≥ 5 mm on perfusion PET correlated with a low risk of incomplete ablation/local progression by both study readers (HR 0.08 and 0.02, p < 0.001).

CONCLUSION: Intraprocedural FDG perfusion PET consistently enabled complete liver tumor microwave ablation margin assessments, and the perfusion PET minimum ablation margin measurements correlated well with local outcomes. Clinical trial registration clinicaltrials.gov (NCT02018107).

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Shyn PB, Cubre AJ, Catalano PJ, et al. F-18 FDG perfusion PET: intraprocedural assessment of the liver tumor ablation margin. Abdom Radiol (NY). 2021. PMID: 33606061. doi:10.1007/s00261-021-02970-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。